Skip to main content
iBio, Inc. logo

iBio, Inc. — Investor Relations & Filings

Ticker · IBIO ISIN · US4510332038 LEI · 529900EW4RXUITGKUT34 US Manufacturing
Filings indexed 690 across all filing types
Latest filing 2022-07-06 Regulatory Filings
Country US United States of America
Listing US IBIO

About iBio, Inc.

https://ibioinc.com/

iBio, Inc. is a preclinical-stage biotechnology company that utilizes a proprietary, AI-driven drug discovery platform to develop novel antibody therapeutics. The company focuses on creating next-generation medicines for obesity and cardiometabolic disorders, aiming to enhance metabolic health. Its technology stack integrates artificial intelligence, machine learning, and advanced computational biology to accelerate the discovery and optimization of biopharmaceuticals for difficult-to-drug targets. The company's internal pipeline consists of therapeutic candidates developed using this platform.

Recent filings

Filing Released Lang Actions
8-K Filing
Regulatory Filings
2022-07-06 English
DEF 14A Filing
Proxy Solicitation & Information Statement
2022-05-24 English
8-K Filing
Regulatory Filings
2022-05-16 English
8-K Filing
Regulatory Filings
2022-05-13 English
10-Q Filing
Interim / Quarterly Report Q3 2022
2022-05-12 English
8-K Filing
Regulatory Filings
2022-05-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.